[go: up one dir, main page]

UY36197A - Caracterización biológica de un producto farmacológico derivado de acetato de glatiramer mediante células de mamífero humano y no humano - Google Patents

Caracterización biológica de un producto farmacológico derivado de acetato de glatiramer mediante células de mamífero humano y no humano

Info

Publication number
UY36197A
UY36197A UY0001036197A UY36197A UY36197A UY 36197 A UY36197 A UY 36197A UY 0001036197 A UY0001036197 A UY 0001036197A UY 36197 A UY36197 A UY 36197A UY 36197 A UY36197 A UY 36197A
Authority
UY
Uruguay
Prior art keywords
human
glatiramer acetate
product derived
mammal cells
biological characterization
Prior art date
Application number
UY0001036197A
Other languages
English (en)
Inventor
Hayden Michael
Grossman Iris
Hasson Tal
Ladkani David
Fadi George Towfic
Sarah Elisabeth Kolitz
Benjamin James Zeskind
Hayardeny Liat
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of UY36197A publication Critical patent/UY36197A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención provee un proceso de caracterización de una sustancia o producto farmacológico relacionado con acetato de glatiramer que comprende los pasos de: a) obtener un lote de la sustancia o producto farmacológico relacionado con acetato de glatiramer; b) poner en contacto células de mamífero con una cantidad de la sustancia o producto farmacológico relacionado con acetato de glatiramer del paso a); y c) determinar el nivel de expresión de al menos uno de los genes descritos en este documento, caracterizando así la sustancia o producto farmacológico relacionado con acetato de glatiramer del paso a).
UY0001036197A 2014-07-01 2015-06-29 Caracterización biológica de un producto farmacológico derivado de acetato de glatiramer mediante células de mamífero humano y no humano UY36197A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462019857P 2014-07-01 2014-07-01
US201462020358P 2014-07-02 2014-07-02
US201462025953P 2014-07-17 2014-07-17
US201462047437P 2014-09-08 2014-09-08
US201462078369P 2014-11-11 2014-11-11
US201562134245P 2015-03-17 2015-03-17
US201562162308P 2015-05-15 2015-05-15

Publications (1)

Publication Number Publication Date
UY36197A true UY36197A (es) 2016-01-29

Family

ID=55020098

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036197A UY36197A (es) 2014-07-01 2015-06-29 Caracterización biológica de un producto farmacológico derivado de acetato de glatiramer mediante células de mamífero humano y no humano

Country Status (6)

Country Link
EP (1) EP3164710A4 (es)
CA (1) CA2952849A1 (es)
IL (1) IL249686A0 (es)
TW (1) TW201610169A (es)
UY (1) UY36197A (es)
WO (1) WO2016004250A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45496A (fr) * 2016-06-17 2019-04-24 Hoffmann La Roche Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
WO2018053109A1 (en) * 2016-09-14 2018-03-22 Teva Pharmaceutical Industries Ltd. Gene expression characterization of a glatiramer acetate related drug product in mammalian and human cells
PE20200868A1 (es) 2017-10-16 2020-08-31 Hoffmann La Roche OLIGONUCLEOTIDOS ANTISENTIDO Y CONJUGADOS QUE LOS COMPRENDEN PARA LA REDUCCION DEL ARNm DE PAPD5 Y PAPD7
CN116637123B (zh) * 2023-06-07 2024-02-13 上海市东方医院（同济大学附属东方医院） 敲降或下调C15orf39基因表达的试剂在制备治疗胃癌的药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2381254B2 (en) * 2007-06-21 2017-07-19 Momenta Pharmaceuticals, Inc. Copolymer assay

Also Published As

Publication number Publication date
WO2016004250A2 (en) 2016-01-07
TW201610169A (zh) 2016-03-16
WO2016004250A3 (en) 2016-03-17
IL249686A0 (en) 2017-02-28
EP3164710A2 (en) 2017-05-10
CA2952849A1 (en) 2016-01-07
EP3164710A4 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
PE20151980A1 (es) Caracterizacion de un medicamento relacionado con acetato de glatiramer
EP3359666C0 (en) EARLY POST-TRANSFECTION ISOLATION OF CELLS TO PREPARE BIOLOGICAL PRODUCTS
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
EA201890013A1 (ru) Способы получения tcr гамма дельтат-клеток
BR112014000965B8 (pt) Método, aparelho e meio de armazenamento não transitório
UY36870A (es) Análogos de insulina novedosos
EA202092987A2 (ru) Липид, содержащий докозапентаеновую кислоту
BR112017007965A2 (pt) método implantado por computador para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; aparelho para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; meio de armazenamento não transitório; programa de computador; kits para medir níveis de expressão de três ou mais genes-alvo da via de sinalização celular de tgf-b em uma amostra de um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; e uso do kit
CO2017006156A2 (es) Un método para manufacturar una proteina de interes, donde dicha proteina es expresada en una celula huesped
MY187050A (en) Cancer cell-specific antibody, anticancer agent, and cancer testing method
MX385004B (es) Composiciones, dispositivos, y métodos de pruebas de sensibilidad del ibs
BR112016024895A2 (pt) fator secretório de proteína com alta eficácia secretória e um vetor de expressão compreendendo o mesmo
UY36197A (es) Caracterización biológica de un producto farmacológico derivado de acetato de glatiramer mediante células de mamífero humano y no humano
MX2016014360A (es) Arquitectura de sensor de biorreactor de unico uso.
CL2016002632A1 (es) Sistema de calibracion de brazo
MX383206B (es) Preparación de anticuerpos de cultivos de célula de ovario de hámster chino para conjugación.
MX389029B (es) Metodos para valorar la pureza de una preparacion de celulas germinales mesenquimales
IL246525B (en) Pomegranate derived cell culture and methods for preparing and using the same
MX375546B (es) Método y aparato in vitro para analizar el comportamiento de sustancias en ambiente fisiológico simulado.
EP4461219A3 (en) Analyte level calibration using baseline analyte level
MX2022003399A (es) Metodo basado en celulas para determinar la potencia de la defibrotida.
CL2016001965A1 (es) Composición coadyuvante anticancerígena que contiene rip3 expresión del promotor como ingrediente activo, método para seleccionar composición coadyuvante anticancerígena para mejorar la sensibilidad de droga anticancerigena, promoviendo la expresión rip3, y metodo para seguimiento de sensibilidad; medicamento contra el cáncer
MX387903B (es) Proceso para la preparacion de acidos 3-hidroxipicolinicos.
EP3543331A4 (en) CELL POPULATION CONTAINING MESENCHYMAL STEM CELLS DERIVED FROM F RATE APPENDICES, METHOD FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION
EP3886911A4 (en) BIOMEMBRANE COATED NANOPARTICLES (BIONP) FOR THE DELIVERY OF ACTIVE PRINCIPLES TO STEM CELLS

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220629